Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

The CARE partner Centre Institut National De La Santé Et De La Recherche Médicale – Vaccine Reserch Institute (INSERM-VRI) published a paper reporting on the design and testing of a protein subunit vaccine CD40.CoV2. The immunogenicity and antiviral efficacy of the vaccine was demonstrated in preclinical testing, and shown to be unaffected by Variants of Concern (VOC) mutations: indicating potential for enriching the available vaccine portfolio by extending the breadth of immune responses against current and emerging VOCs.

To learn more, click here: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

The CARE partner Centre Hospitalier Universitaire Vaudois (CHUV) in collaboration with Lausanne University Hospital published a paper reporting on the durability of neutralizing antibody responses elicited by messenger RNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) against the SARS-CoV-2 variants of concern (VOCs) in immunocompromised patients and healthy controls. The study showed a loss of neutralizing antibody response against the circulating VOCs at 6 months after vaccination, the loss being demonstrably greater for immunocompromised patients.

To learn more, click here: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Published in MDPI: Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication

The CARE partners Katholieke Universiteit Leuven (KUL), Universiteit Utrecht (UU), University Of Dundee (UNIVDUN), Universitaet Zu Luebeck (UZL) in collaboration with a number of other organisations published a paper reporting on the conduct of a high-throughput screening of a 160 K compound library against SARS-CoV-2, yielding a promising hit. Antiviral profiling revealed this candidate was active against various beta-coronaviruses and preliminary mode-of-action experiments demonstrated that it interfered with viral entry.

To learn more, click here: Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication

Published in CellPress iScience: Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates 

The CARE partners Institut National De La Santé Et De La Recherche Médicale – Vaccine Research Institute (INSERM-VRI) and Commissariat À L’énergie Atomique Et Aux Énergies Alternatives (CEA) published a paper reporting how PET and CT imaging provide an additional readout to assess therapy efficacy as demonstrated through monitoring the early phase of COVID-19 in 76 SARS-CoV-2 infected macaques. The comparison of CT and PET data from previous COVID-19 treatments or vaccines tested in NHP, to this large cohort of untreated animals demonstrated the value of in vivo imaging in preclinical trials.

To learn more, click here: Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates

CARE 2^nd Annual meeting

CARE 2^nd Annual meeting was successfully held in Paris on 9-10 June 2022, in presence of CARE Scientific and Ethics Advisory Board and IHI Project Officer.  Around 60 people attended in person and 50 remotely to listen to and to discuss the project progress, achievements and next steps.